Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Min HUANG received her Ph.D. degree from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. She then did her post-doctoral training at Dana-Farber Cancer Institute, Harvard Medical School. She is currently a professor and principal investigator in the Cancer Research Center at SIMM.

Dr. Huang’s research interest is to exploit metabolic vulnerabilities of both cancer cells and the tumor microenvironment for cancer therapy. She has published over 70 peer-reviewed research articles and invited reviews in journals including Cancer Cell, Mol Cell, Nat Commun, Cell Res, Cancer Res etc. She is also the co-inventor of several innovative anticancer drugs that are currently undergoing clinical trials in both China and USA.

Education

2008.01 - 2011.02 Postdoctoral Research Fellow in Radiation Oncology Dana-Farber Cancer Institute, Harvard Medical School

Boston, USA

2002.09 - 2007.07 Ph.D. degree in Pharmacology Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai, China

1998.09 - 2002.07 B.S. degree in Pharmacy China Pharmaceutical University, Nanjing, China

Work Experience

2022.08-present Principal Investigator, Department of Anti-tumor Pharmacology Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2013.01-present Professor, Department of Anti-tumor Pharmacology Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2011.10-2012.12 Associate Professor, Department of Anti-tumor Pharmacology Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2011.03-2013.10 Assistant Professor, Department of Anti-tumor Pharmacology Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Research Directions

1. Revealing the rewired metabolism in cancer cells and the tumor microenvironment

2. Discovering targeted therapies exploiting metabolic vulnerabilities for cancer treatment

Grants & Research Projects

1. Distinguished Young Scholars, National Natural Science Foundation of China, 2023.01-2027.12, PI

2. Training Program of the Major Research Plan, National Natural Science Foundation of China, 2020.01-2022.12, PI

3. National Science and Technology Major Project, Chinese Ministry of Science and Technology, 2019.01-2020.12, Sub-project leader

4. General Program, National Natural Science Foundation of China, 2016.01-2019.12, PI

5. Mainland-Macao Science and Technology Cooperation Program, Chinese Ministry of Science and Technology, 2015.04-2018.03, PI

6. Excellent Young Scholars, National Natural Science Foundation of China, 2013.01-2015.12, PI

Achievements

Dr. Min Huang’s group has revealed previously unrecognized metabolic vulnerabilities of different types of oncogene-driven cancer, including KRAS-, EGFR-, FGFR- and IDH-altered cancers. Based on these findings, she collaborates with medicinal chemists to develop inhibitors targeting metabolic enzymes, yielding several drug candidates that have entered clinical studies.

morefold

Social Titles

1. Editorial Board, Acta Pharmaceutica Sinica B

2. Editorial Board, Progress in Pharmaceutical Sciences

3. Standing Committee Member, The Society of Anti-Cancer Agent, China Anti-Cancer Association

morefold

Awards & Honors

1. CNPHARS-SERVIER Young Investigator Awards in Pharmacology

2. WuXi AppTec Life Science Research Award

3. Shanghai Women Innovation Award

morefold

Pubilcations

Full Publication List

Selected Publications

1. Wang X, Chen Z, Xu J, Tang S, An N, Zhang Y, Zhang S, Zhang Q, Shen Y, Chen S, Lan X, Wang T, Zhai L, Cao S, Guo S, Liu Y, Bi A, Chen Y, Gai X, Duan Y, Zheng Y, Fu Y, Li Y, Yuan L, Tong L, Mo K, Wang M, Lin SH, Tan M, Luo C, Chen Y, Liu J, Zhang Q, Li L, Huang M*. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Res. 2022,32(7): 638-658. (Featured article, cover story)

2. Liu Z, Liu Y, Qian L, Jiang S, Gai X, Ye S, Chen Y, Wang X, Zhai L, Xu J, Pu C, Li J, He F, Huang M*, Tan M*. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell. 2021, 81(19): 4076-4090. (Featured article)

3. Jin N, Bi A, Lan X, Xu J, Wang X, Liu Y, Wang T, Tang S, Zeng H, Chen Z, Tan M, Ai J, Xie H, Zhang T, Liu D, Huang R, Song Y, Leung LH, Yao XJ, Ding J, Geng M*, Lin SH*, Huang M*. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Nat Commun. 2019, 10(1): 2701.

4. Qu J, Sun W, Zhong J, Lv H, Zhu M, Xu J, Jin N, Xie Z, Tan M, Lin SH, Geng M, Ding J*, Huang M*. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells. J Cell Biol. 2017, 216(2):409-424. (Spotlight article)

5. Zeng H, Qu J, Jin N, Xu J, Lin C, Chen Y, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M*, Ding J*, Geng M*. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer. Cancer Cell. 2016, 30(3): 459-73.

6. Sun W, Xie Z, Liu Y, Zhao D, Wu Z, Zhang D, Lv H, Tang S, Jin N, Jiang H, Tan M, Ding J, Luo C*, Li J*, Huang M*, Geng M*. JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res 2015, 75(22): 4923-36.

7. Zhang D, Jin N, Sun W, Li X, Liu B, Xie Z, Qu J, Xu J, Yang X, Su Y, Tang S, Han H, Chen D, Ding J, Tan M, Huang M*, Geng M*. Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity. Oncogene. 2017, 36(20): 2900-2909.

8. Huang M, Shen A, Ding J*, Geng M*. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014; 35(1): 41-50. Invited review

9. Huang M, Kim JM, Shiotani B, Yang K, Zou L, D'Andrea AD. The FANCM/FAAP24 Complex Is Required for the DNA Interstrand Crosslink-Induced Checkpoint Response. Mol Cell. 2010, 39(2): 259-268.

10. Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Zhang J, Shen H, Lin L, Lu W, Ding J. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res. 2007, 13(4): 1298-1307. (Cover story)

morefold